USE OF THE NEUROTOXIC COMPONENT OF A BOTULINUM TOXIN FOR THE TREATMENT OF PAIN ASSOCIATED WITH MUSCLE ACTIVITY OR CONTRACTURE
A method and composition for treating a patient suffering from a disease, disorder or condition and associated pain include the administration to the patient of a therapeutically effective amount of a neurotoxin selected from a group consisting of Botulinum toxin types A, B, C, D, E, F and G.
1 . A method for treating a pain associated with a muscle activity or contracture, the method comprising the step of administering to a patient a therapeutically effective amount of the neurotoxic component of a botulinum toxin to thereby treat the pain associated with the muscle activity or contracture, wherein the neurotoxic component administered to the patient has been purified from a botulinum toxin obtained by fermenting Clostridium botulinum.
2 . The method of claim 1 wherein the neurotoxic component is the neurotoxic component of a botulinum toxin selected from the group consisting of botulinum toxin types A, B, C, D, E, F and G.
3 . The method of claim 1 , wherein the botulinum toxin is botulinum toxin type A.
4 . The method of claim 1 , wherein between about 1 unit and about 250 units of the neurotoxic component is administered.
5 . The method of claim 1 , wherein alleviation of the pain associated with a muscle activity or contracture occurs in about 1 to about 7 days.
6 . The method of claim 1 , wherein the neurotoxic component has a molecular weight of about 150 kilodaltons.
7 . The method of claim 1 , wherein the muscle activity or contracture is a muscle spasm.
8 . The method of claim 1 , wherein the pain is a low back pain.
9 . The method of claim 1 , wherein the pain is a myofacial pain.
10 . The method of claim 1 , wherein the pain is a spasticity pain.
11 . The method of claim 1 , wherein the pain is a dystonia pain.
12 . The method of claim 1 , wherein the pain is an arthritis pain.
13 . The method of claim 1 , wherein the pain is a headache.
14 . The method of claim 1 , wherein the pain is a sports injury pain
15 . The method of claim 1 , wherein the pain is secondary to stroke.
16 . The method of claim 1 , wherein the pain is associated with a smooth muscle spasm.
17 . The method of claim 16 , wherein the pain is associated with a smooth muscle spasm of a gastrointestinal smooth muscle.
18 . The method of claim 1 , wherein the neurotoxic component is administered by local administration.
19 . A method for treating a pain associated with a muscle activity or contracture, the method comprising the step of administering to a patient a therapeutically effective amount of the neurotoxic component of only a botulinum toxin type A to thereby treat the pain associated with the muscle activity or muscle contracture, wherein the neurotoxic component administered to the patient has been purified from a botulinum toxin obtained by fermenting a Clostridium botulinum bacterium.
20 . The method of claim 19 , wherein the neurotoxic component has a molecular weight of about 150 kilodaltons.
21 . The method of claim 19 , wherein the muscle activity or contracture is a muscle spasm.
22 . The method of claim 19 , wherein the pain is a low back pain.
23 . The method of claim 19 , wherein the pain is a myofacial pain.
24 . The method of claim 19 , wherein the pain is a spasticity pain.
25 . The method of claim 19 , wherein the pain is a dystonia pain.
26 . The method of claim 19 , wherein the pain is an arthritis pain.
27 . The method of claim 19 , wherein the pain is a headache.
28 . The method of claim 19 , wherein the pain is a sports injury pain
29 . The method of claim 19 , wherein the pain is secondary to stroke.
30 . The method of claim 19 , wherein the pain is associated with a smooth muscle spasm.
31 . The method of claim 30 , wherein the pain is associated with a smooth muscle spasm of a gastrointestinal smooth muscle.
32 . The method of claim 19 , wherein the neurotoxic component is administered by local administration.
33 . A method for treating a pain associated with a muscle activity or contracture, the method comprising the step of administering to a patient a therapeutically effective amount of the neurotoxic component from a single botulinum toxin type to thereby treat the pain associated with the muscle activity or muscle contracture, wherein the neurotoxic component administered to the patient has been purified from a botulinum toxin obtained by fermenting a Clostridium botulinum bacterium.
34 . The method of claim 33 , wherein the botulinum toxin type is selected from the group consisting of the botulinum toxin types A, B, C, D, E, F and G.
35 . The method of claim 33 , wherein the botulinum toxin type is botulinum toxin type A.
36 . The method of claim 33 , wherein the neurotoxic component has a molecular weight of about 150 kilodaltons.
37 . The method of claim 33 , wherein the muscle activity or contracture is a muscle spasm.
38 . The method of claim 33 , wherein the pain is a low back pain.
39 . The method of claim 33 , wherein the pain is a myofacial pain.
40 . The method of claim 33 , wherein the pain is a spasticity pain.
41 . The method of claim 33 , wherein the pain is a dystonia pain.
42 . The method of claim 33 , wherein the pain is an arthritis pain.
43 . The method of claim 33 , wherein the pain is a headache.
44 . The method of claim 33 , wherein the pain is a sports injury pain
45 . The method of claim 33 , wherein the pain is secondary to stroke.
46 . The method of claim 33 , wherein the pain is associated with a smooth muscle spasm.
47 . The method of claim 46 , wherein the pain is associated with a smooth muscle spasm of a gastrointestinal smooth muscle.
48 . The method of claim 33 , wherein the neurotoxic component is administered by local administration.